MedTrace Logo

Impact of the Introduction of ORKAMBI on Anxiety, Depression, Quality of Life and Adherence of Adolescents and Young Adults

NCT03659214 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19

Last updated 2025-11-20

No results posted yet for this study

Summary

The aim of this project is to evaluate the psychological reshuffle induced by ORKAMBI. The particular focus of this study is the consequence of its introduction on anxiety, depression, quality of life and adherence to all cystic fibrosis (CF) treatment. To answer this question investigators will monitor the psychological function of CF adolescents and young adults treated with ORKAMBI and compare them to CF adolescents and young adults not treated with ORKAMBI.

Conditions

Interventions

BEHAVIORAL

Questionnaires

Answering 4 questionnaires : anxiety, depression, quality of life and adherence

Sponsors & Collaborators

  • VERTEX Pharmaceutical

    collaborator UNKNOWN

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Maya KIRSZENBAUM, Psychologist · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
12 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2022-01-19
Completion
2022-01-19

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03659214 on ClinicalTrials.gov